Pyxis Oncology (PYXS) Stock: Buy, Sell, or Hold?
PYXS - Pyxis Oncology, Inc. Common Stock
$1.71
-0.05 (-2.63%)
▼
5d:
-4.79%
30d:
-46.78%
90d:
-34.34%
HOLD
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 02, 2026
10d
Get Alerted When PYXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PYXS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PYXS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PYXS is currently trading at $1.71, which is considered oversold relative to its 30-day fair value range of $1.82 to $3.10.
Technical Outlook: Technically, PYXS is in a uptrend. Immediate support is located at $1.66, while resistance sits at $2.08.
Market Sentiment: PYXS scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.67 (+392.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PYXS is in a uptrend. Immediate support is located at $1.66, while resistance sits at $2.08.
Market Sentiment: PYXS scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.67 (+392.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.82 -
$3.10
Company Quality Score
59/100
(HOLD)
Options IV Signal
57th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 57th percentile)
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 392.4% below Wall St target ($8.67)
- CAUTION: Bottoming setup, but lagging the sector by 28% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.82 -
$3.10
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.54
(31.3%)
Support & Resistance Levels
Support Level
$1.66
Resistance Level
$2.08
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.59
Wall Street Target
$8.67
(+392.4%)
Share & Embed Analysis
Last updated: October 22, 2026 1:22 PM ET
Data refreshes hourly during market hours. Next update: 2:22 PM
Data refreshes hourly during market hours. Next update: 2:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PYXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 71 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
